Metformin down-regulates hepatic apoA5 expression and reductes hepatic TG level, which contributes to prevention of NAFLD development, and involves the AMPK/LXRα signaling pathway. The gene discussed is NR1H3; the disease is metabolic dysfunction-associated steatotic liver disease.